Back

Cardiovascular risk profiles and outcomes in patients with type 2 diabetes - Implications for choice of new diabetes therapies

31 August 2019 (14:20 - 14:37)
Organised by:
Congress Presentation Part of: The right glucose-lowering drugs for the right patient Epidemiology ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Mariam Elmegaard

Herlev and Gentofte Hospital, Copenhagen (Denmark)

3 More presentations in this session

Presentation thumbnail
State of the Art in antidiabetic treatment to prevent CVD
Professor A. Norhammar (Stockholm, SE)
Slides Video
Presentation thumbnail
Albuminuria as a predictor of incident ischemic stroke and myocardial infarction in patients with type 2 diabetes but without cardiovascular disease: A Danish cohort study
Mrs M. Fangel (Aalborg, DK)
Abstract Slides Video
Presentation thumbnail
Heart failure risk stratification and efficacy of dapagliflozin in patients with type 2 diabetes mellitus
Doctor D. Berg (Boston, US)
Abstract Slides Video

Access the full session

Session thumbnail
The right glucose-lowering drugs for the right patient

The Event

Event poster

ESC Congress 2019

31 August 2019 14:20 CET
You may be interested in
thumbnail
Congress Presentation
Association of kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus: insights from the EMPA-REG OUTCOME trial
29 June 2021
thumbnail
Congress Presentation
The frequency of coronary artery atherosclerotic plaques in patients with newly diagnosed type 2 diabetes mellitus
26 April 2024
thumbnail
Webinar
EAPC Webinar: Type 2 Diabetes and cardiovascular risk
12 March 2019
thumbnail
Congress Presentation
Adherence and discontinuation of sglt2-inhibitors and glp1-r agonists in patients with type 2 diabetes with and without cardiovascular disease
27 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources